The DNA Sequencing Facility (DSF) provides investigators with high quality DNA sequencing. In calendar year 2009, the Facility was used by 43 peer-reviewed, funded investigators across four of the Center's five Research Programs. Ninety-eight and one-half percent (98.5%) of use is in support of peer-reviewed, funded investigators. Hardy (Immune Cell Development and Host Defense (ICDHD) Program) assumed direction of the Facility in 1993. In 2004 all automated sequencers were replaced by a single ABI 3100 capillary instrument, providing more reliable high-throughput sequencing. The ABI 3100 was upgraded to a model 3130 in 2007. The DSF provides Fox Chase Cancer Center (FCCC) investigators with computer-readable sequences of their DNA samples in a timely and cost effective manner. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes. The volume of usage of the Facility has continued at a high level averaging 16,000 sequences per year over the last five years. Equitable access and operational oversight of the Facility are assured by recommendations from a Facility Advisory Committee (FAC) and the Facility Parent Oversight Committee (FPOC).
Automated DNA sequencing is a necessary tool in Biomedical Research. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes.
|Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :|
|Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :|
|Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78|
|Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9|
|Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50|
|Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81|
|Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64|
|Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9|
|Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86|
|Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35|
Showing the most recent 10 out of 884 publications